The meeting of the German Society of Human Genetics (gfh) was held in Weimar, Germany this week and of course the attendees had the opportunity to visit the joined booth of MetaSystems and MetaSystems Probes. Main topics of the exhibition have been the latest advancements of the Neon case and imaging platform and RapidHyb, the revolutionary fast hybridization times of MetaSystems Probes' FISH probes.
XL JAK2 BA
Break Apart Probe
- Order Number
- Package Size
- 100 µl (10 Tests)
Patients with clinical characteristics of CML lacking a BCR/ABL fusion gene are usually
referred to as having atypical CML. Most commonly diverse tyrosine kinase genes as the
receptors FGFR1, PDGFRA, or PDGFRB are involved. In addition the Janus (tyrosine)
kinases (JAK) can be deregulated in leukemia/lymphoma by copy number alterations, mutations and chromosomal translocations.
Chromosomal translocations targeting JAK2 are rare but recurrent abnormalities in myeloproliferative neoplasms, acute myeloid leukemia, acute lymphoblastic leukemia and lymphoma. In cell line models and primary patient material it could be shown that treatment with ruxolitinib has significant activity against JAK2 activated by gene rearrangement and presents evidence for potential activity against cells with JAK2 amplification.
- Chronic Myelogenous Leukemia and Myeloproliferative Neoplasms (CML/MPN)
- Acute Myelogenous Leukemia (AML)
- Acute Lymphoblastic Leukemia (ALL)
Two green-orange fusion signals (2GO).
Aberrant Cell (typical results):
One green (1G), one orange (1O), and one green-orange (1GO) fusion signal, indicating a chromosome break in the JAK2 locus.
- Bousquet et al (2005) Oncogene 24: 7248- 7252
- Chase et al (2012) Haematologica 93: 404- 408
- Ehrentraut et al (2013) PLOSone 8: e53767